Lepodisiran, Muvalaplin, and the Lp(a) Moment: What New Cholesterol Drugs Mean for Longevity Clinics

If you are evaluating lepodisiran, Lp(a), and longevity clinics, start with the most important point: the new drugs are exciting, but they are not clinic menu items today.

Lilly’s investigational siRNA lepodisiran has reported Phase 2 data showing very large and durable reductions in lipoprotein(a), usually written Lp(a). Lilly’s oral investigational drug muvalaplin has also shown substantial Phase 2 reductions. These are serious cardiovascular-prevention developments, not “anti-aging shots.”

For longevity clinics, the lesson is immediate but different: clinics should be getting much better at identifying inherited cardiovascular risk now. That means measuring Lp(a), interpreting ApoB and LDL-C properly, reviewing family history, using coronary artery calcium or plaque imaging selectively, and referring high-risk patients to preventive cardiology when needed.

The drugs may change practice later. The screening logic should change now.

Medical note: this article is a buyer’s guide, not personal medical advice. Lepodisiran and muvalaplin are investigational. Do not use this article to seek unapproved access or change treatment without a qualified physician.

Quick answer: what should longevity-clinic buyers know?

Lepodisiran and muvalaplin target Lp(a), an inherited cardiovascular risk factor that is often missed by standard cholesterol discussions. Lp(a) is mostly genetic, is not meaningfully lowered by lifestyle, and can increase risk even when LDL-C looks reasonable.

In 2025, Lilly reported that lepodisiran lowered Lp(a) by an average of 93.9% from baseline over days 60–180 at the highest tested Phase 2 dose, with some reductions sustained for nearly 18 months.¹ ACC’s ALPACA summary described lepodisiran as an extended-duration small interfering RNA administered subcutaneously, with no serious adverse events attributed to the drug in the Phase 2 study.²

Muvalaplin is different: it is an investigational once-daily oral small molecule designed to inhibit Lp(a) formation. Lilly reported placebo-adjusted Lp(a) reductions of up to 85.8% by an intact Lp(a) assay at 12 weeks in Phase 2.³

But the caveat is crucial: lowering a biomarker is not the same as proving fewer heart attacks, strokes, or deaths. Phase 3 outcomes trials are the step that matters.

Why Lp(a) matters in longevity medicine

Longevity medicine often talks about inflammation, glucose, biological age, VO₂ max, sleep, and body composition. Those are important. But cardiovascular disease remains one of the largest determinants of healthy lifespan, and Lp(a) is one of the most under-discussed inherited risk markers in preventive care.

Lp(a) is an LDL-like particle with apolipoprotein(a) attached. It is produced mainly in the liver and has atherogenic, pro-inflammatory, and pro-thrombotic properties. The American College of Cardiology describes Lp(a) as an independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis.⁴

The practical reason it matters: a patient can have “normal” LDL-C and still carry high inherited risk through Lp(a). That is exactly the kind of blind spot a serious longevity health assessment should catch.

Unlike triglycerides, glucose, blood pressure, or body composition, Lp(a) is not highly responsive to diet and exercise. The European Atherosclerosis Society consensus statement notes that Lp(a) concentration is predominantly genetically determined and recommends measuring it at least once in adults.⁵

That does not make lifestyle irrelevant. It makes the interpretation different. If Lp(a) is high, the clinic’s job is to lower the patient’s total modifiable risk load: ApoB, LDL-C, blood pressure, insulin resistance, smoking, sleep apnea, visceral fat, fitness, and inflammatory burden.

What lepodisiran is

Lepodisiran is an investigational small interfering RNA, or siRNA, therapy designed to reduce production of apolipoprotein(a), a key component of Lp(a). It is not a statin. It is not a supplement. It is not a general longevity injection.

In the Phase 2 ALPACA study, 320 adults with elevated Lp(a) were randomized to placebo or lepodisiran regimens. Doses included 16 mg, 96 mg, and 400 mg at baseline and day 180, with another group receiving 400 mg at baseline and placebo at day 180. Lilly reported that the highest tested dose reduced Lp(a) by an average of 93.9% over days 60–180.¹

ACC’s summary of the ALPACA results adds useful clinical context: participants had a mean age of 62.7 years, median baseline Lp(a) of 253.9 nmol/L, and many were already high-risk — 48% had coronary artery disease and 31% had a previous myocardial infarction.²

The durability is why cardiology is paying attention. Lilly reported that participants receiving 400 mg at baseline and day 180 had average Lp(a) reductions of 94.8% over days 30–360, remained 91.0% below baseline at day 360, and 74.2% below baseline at day 540.¹

The study was also published in the New England Journal of Medicine, which is why this moved from biotech noise into mainstream cardiovascular prevention discussion.⁶

Still, lepodisiran remains investigational. Lilly says the ACCLAIM-Lp(a) Phase 3 cardiovascular outcomes program is enrolling to test whether Lp(a) lowering translates into fewer cardiovascular events.¹

That is the line credible clinics should repeat until outcomes data arrive.

What muvalaplin adds

Muvalaplin is Lilly’s other major Lp(a) program, and it matters because the route is different.

Instead of a long-acting injected siRNA, muvalaplin is an investigational once-daily oral small molecule. Lilly describes it as a selective inhibitor of Lp(a) formation that blocks the initial interaction between apolipoprotein(a) and apolipoprotein B.³

In Lilly’s Phase 2 report, muvalaplin reduced Lp(a) at 12 weeks by 47.6% at 10 mg, 81.7% at 60 mg, and 85.8% at 240 mg using an intact Lp(a) assay. Using an apo(a) assay, reductions were lower but still substantial: 40.4%, 70.0%, and 68.9% respectively.³

Why does that matter for longevity-clinic buyers? If an oral Lp(a)-lowering drug eventually proves outcomes benefit and is approved, it may become easier to integrate into preventive cardiology than an infrequent injection. But that is a future possibility, not a 2026 clinic offer.

For now, muvalaplin adds confidence that Lp(a) has become a serious therapeutic target. It does not justify clinics implying that patients can already buy a proven Lp(a)-lowering longevity pill.

Biomarkers are not outcomes

The longevity world often makes one recurring mistake: it sees a biomarker move and assumes lifespan changed.

Lp(a) is a strong inherited risk marker. Large reductions are scientifically meaningful. But patients should distinguish three questions:

Question	Current answer
Can lepodisiran lower Lp(a) substantially?	Phase 2 data suggest yes.
Can muvalaplin lower Lp(a) substantially?	Phase 2 data suggest yes.
Do these drugs reduce heart attacks, strokes, aortic stenosis progression, or mortality?	Not proven yet; outcomes trials are needed.

ACC’s ALPACA summary quotes the central unresolved question from a related NEJM editorial: whether substantial Lp(a) reduction will reduce cardiovascular events to a clinically relevant degree.²

That is the clinical threshold. Longevity clinics should not shortcut it.

What a serious longevity clinic should do now

A serious clinic should not be offering lepodisiran or muvalaplin as “longevity drugs” today. It should be building a better inherited cardiovascular risk workflow.

That workflow should include:

1. One-time Lp(a) measurement. Especially for people with family history of premature cardiovascular disease, unexplained risk, high LDL-C, aortic stenosis, or early plaque.
2. ApoB, LDL-C, non-HDL-C, triglycerides, and metabolic context. ApoB helps quantify atherogenic particle burden. Lp(a) does not replace it.
3. Blood pressure and glycemic risk. High Lp(a) plus hypertension or insulin resistance is not the same risk profile as isolated high Lp(a).
4. Family history. Premature heart attack, stroke, sudden death, familial hypercholesterolemia, and aortic stenosis matter.
5. Selective imaging. Coronary artery calcium, coronary CT angiography, carotid ultrasound, or other imaging may be useful in selected patients, but not as a reflex upsell.
6. Cardiology referral. High Lp(a), early plaque, symptoms, strong family history, or complex lipid patterns should trigger preventive cardiology input.
7. Risk-factor intensification today. Until specific Lp(a) drugs are approved, clinics should optimize proven levers: LDL/ApoB lowering, blood pressure control, smoking cessation, exercise, sleep apnea treatment, body composition, and diabetes prevention.
8. Trial literacy. Clinics should know which trials are active and what eligibility means, but should not imply access outside legitimate research pathways.

This is where advanced assessments can be useful. A clinic that already offers physician-led cardiovascular screening, advanced lipids, imaging, and longitudinal follow-up is better positioned than a clinic selling generic “anti-aging” panels. For broader context, see our guides to biological-age testing technologies and longevity-clinic standards for diagnostics, AI, and biomarkers.

Use the WLC clinic directory, rankings, compare tool, and find-your-clinic guide to compare whether a clinic is actually strong in diagnostics and preventive medicine rather than just treatment marketing.

What patients should not believe

The Lp(a) moment will create marketing abuse. Watch for these claims:

• “The new Lilly cholesterol shot is available at our longevity clinic.”
• “Lp(a) lowering is proven to reverse aging.”
• “A supplement stack can normalize inherited Lp(a).”
• “If LDL-C is normal, your cardiovascular risk is handled.”
• “Lp(a) is just another lifestyle biomarker.”
• “We can treat high Lp(a) without cardiology-grade risk assessment.”

None of those claims are responsible.

The right framing is more sober: Lp(a) is an inherited cardiovascular risk factor. Testing can identify risk that routine panels miss. New drugs may become important if outcomes trials succeed. Until then, clinics should optimize proven risk factors and avoid selling investigational science as available anti-aging therapy.

Other clinics worth considering

Human Longevity Inc. is relevant if you want a data-rich preventive assessment model with advanced diagnostics, genomics, imaging, and physician interpretation. For Lp(a), the key question is whether the program translates lipid and imaging data into a practical prevention plan.

Fountain Life is relevant for buyers interested in advanced imaging, biomarkers, and proactive detection. The due-diligence question is whether cardiovascular findings lead to appropriate specialist referral and evidence-based follow-up rather than just more screening.

Biograph is relevant for a high-touch longitudinal assessment model. For inherited cardiovascular risk, ask how often lipids are reviewed, whether ApoB and Lp(a) are standard, and how imaging findings are integrated over time.

None of these clinics should be judged by whether they can sell lepodisiran or muvalaplin. They should be judged by whether they can detect inherited cardiovascular risk early and manage it responsibly.

Buyer checklist: questions to ask a clinic about Lp(a)

Before booking a longevity clinic, ask:

1. Do you measure Lp(a) as part of the baseline assessment?
2. Do you report Lp(a) in nmol/L, mg/dL, or both, and how do you interpret thresholds?
3. Do you measure ApoB, non-HDL-C, LDL-C, triglycerides, hs-CRP, blood pressure, and glycemic risk alongside Lp(a)?
4. How do you handle a high Lp(a) result if LDL-C looks normal?
5. Do you review family history of premature heart disease, stroke, sudden death, and aortic stenosis?
6. When do you recommend CAC scoring, CT angiography, carotid imaging, or other plaque assessment?
7. Do you have a preventive cardiologist or lipid specialist referral pathway?
8. What do you recommend today, before specific Lp(a)-lowering drugs are approved?
9. Do you discuss investigational therapies without implying access or proven outcomes?
10. Will you coordinate results with my primary physician or cardiologist?

If a clinic cannot answer these clearly, it may not be ready to manage inherited cardiovascular risk.

FAQ

Is Lp(a) the same as LDL cholesterol?

No. Lp(a) is an LDL-like particle with an additional apolipoprotein(a) component. LDL-C can look acceptable while Lp(a) remains high, which is why Lp(a) can reveal inherited cardiovascular risk that a standard lipid panel may miss.

Is lepodisiran approved for longevity clinics?

No. Lepodisiran is investigational. Phase 2 data show large and durable Lp(a) reductions, but cardiovascular outcomes trials are still needed before approval and routine clinical use.

Can lifestyle lower Lp(a)?

Lifestyle changes usually do not meaningfully lower genetically determined Lp(a). They still matter because blood pressure, LDL-C, ApoB, insulin resistance, smoking, exercise, and body composition influence overall cardiovascular risk.

Should everyone test Lp(a)?

Many expert groups support at least one adult Lp(a) measurement, especially for people with premature cardiovascular disease, family history, high LDL-C, aortic stenosis, or unexplained risk. A longevity clinic should be able to explain when and why it tests Lp(a).

Bottom line

Lepodisiran and muvalaplin are part of a genuine cardiovascular prevention story. They may become important if Phase 3 outcomes trials show that lowering Lp(a) reduces events.

But the best longevity-clinic response in 2026 is not to hype access to investigational drugs. It is to stop missing inherited cardiovascular risk.

A credible clinic should measure Lp(a), interpret it with ApoB and LDL-C, consider family history, use imaging selectively, coordinate with preventive cardiology, and be honest about what is proven today versus what remains experimental.

That is the real Lp(a) moment for longevity medicine.

Footnotes

1. Lilly’s lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels, Lilly / PRNewswire, 2025. ↩ ↩² ↩³ ↩⁴

2. ALPACA: Single Injection of Novel Lepodisiran Reduces Lp(a) Concentration, American College of Cardiology, 2025. ↩ ↩² ↩³

3. Lilly’s muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose, Lilly, 2024. ↩ ↩² ↩³

4. An Update on Lipoprotein(a): The Latest on Testing, Treatment, and Guideline Recommendations, American College of Cardiology, 2023. ↩

5. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement, European Heart Journal, 2022. ↩

6. Lepodisiran — NEJM paper, New England Journal of Medicine, 2025. ↩